BenzingaMay 20, 9:50 AM ET▲ Positive
3-year Phase 1/2a data for OpRegen shows partial retinal structure restoration and disease stabilization in geographic atrophy, challenging the view that the condition is irreversible.
Lineage Cell Therapeutics news
$0.9557+0.87%
Close Sep 30, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Lineage Cell Therapeutics
No recent articles focused on Lineage Cell Therapeutics.
Also mentions LCTX
Articles that tag LCTX but are mainly about other companies.
BenzingaApr 10, 9:55 AM ET▲ Positive
Company is expanding its AlloSCOPE platform into Type 1 diabetes islet therapy and achieved a milestone with Roche's Genentech collaboration for geographic atrophy treatment, demonstrating pipeline expansion in age-related diseases.
BenzingaMar 18, 10:00 AM ETNeutral
Mentioned as a competitor advancing allogeneic cell therapies with proprietary manufacturing platform, but no specific news or developments disclosed in this article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology